Filter By Category
Archives
Share on -
DULANERMIN
Generic Name: DULANERMIN
ABSTRACT -
Dulanermin is a recombinant human soluble TRAIL/Apo2 ligand protein investigated as an anticancer therapy that activates TRAIL receptors and apoptotic signaling in susceptible tumor cells.
DOSAGE -
No approved dosage. Administered intravenously in oncology clinical trials according to protocol.
SIDE EEFECTS -
- Fatigue
- Nausea
- Fever or chills
- Hepatic enzyme changes
- Infusion-related symptoms
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Infusion hypersensitivity
- Rash or urticaria
- Dyspnea or bronchospasm
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- Other anticancer therapies may increase overlapping toxicity
- Immunosuppressants may alter biologic response
- Avoid live vaccines during intensive cancer therapy unless directed
PREAUTONS–
- Investigational biologic; use only in controlled research
- Monitor liver function and infusion reactions
- Assess tumor type and TRAIL receptor biology when relevant
WARNINGS –
- Not approved for routine treatment
- Potential serious infusion reactions and hepatic toxicity
Share on -
. Developed by